Catalyst Funds Management Pty Ltd Takes $91,000 Position in OPKO Health, Inc. (NASDAQ:OPK)

Catalyst Funds Management Pty Ltd bought a new position in OPKO Health, Inc. (NASDAQ:OPK) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 61,600 shares of the biotechnology company’s stock, valued at approximately $91,000.

Several other institutional investors have also recently bought and sold shares of the company. Rubric Capital Management LP raised its holdings in OPKO Health by 9.6% in the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares during the period. PFG Investments LLC raised its holdings in OPKO Health by 9.4% in the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company’s stock worth $1,707,000 after acquiring an additional 99,795 shares during the period. Clearline Capital LP bought a new position in OPKO Health in the 3rd quarter worth $1,083,000. Barclays PLC raised its holdings in OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares during the period. Finally, Essential Planning LLC. bought a new position in OPKO Health in the 4th quarter worth $506,000. Institutional investors own 64.63% of the company’s stock.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00. Following the transaction, the chief executive officer now owns 213,036,477 shares in the company, valued at approximately $315,293,985.96. The trade was a 0.24 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have acquired 764,971 shares of company stock worth $1,145,692. Corporate insiders own 47.26% of the company’s stock.

Wall Street Analysts Forecast Growth

OPK has been the topic of several recent analyst reports. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.74 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.16 and a beta of 1.70. The company’s fifty day moving average is $1.62 and its two-hundred day moving average is $1.57. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.